ESC 365 - Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis

Open Access

Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis

Session: Cardiac amyloidosis uncovered: from clues to cutting-edge care

Topic: Clinical

Speaker: Doctor M. Merlo (Trieste, IT)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Marco Merlo

United Hospitals of Trieste University Hospital, Trieste (Italy)

4 presentations

0 follower

2 more presentations in this session

Cardiac resynchronization therapy, remodeling and outcome in patients with amyloid transthyretin cardiomyopathy

Speaker: Doctor A. Aimo (Pisa, IT)

Malnutrition, frailty, and physical performance in transthyretin cardiac amyloidosis: insights from a prospective multicenter cohort study

Speaker: Doctor C. Fumagalli (Florence, IT)

Access the full session

Cardiac amyloidosis uncovered: from clues to cutting-edge care

Speakers: Doctor M. Merlo, Doctor A. Aimo, Doctor C. Fumagalli

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources